| 발표일자: |
2016년 11월 4일(금) ~ 11월 6일(일) |
| 발표번호: |
P(판넬)-016 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 제2형 당뇨병 및 당뇨망막병증 환자에서 스타틴 약제 복용과 고중성지방혈증이 당뇨황반부종에 미치는 영향 |
| (1) 아주대학교 의과대학 안과학교실, (2) 서울대학교병원 망막혈관실험실, (3) 서울대학교 의과대학 의과학과, (4) 서울대학교 의과대학 안과학교실 |
| 김승우(1), 정유리(1), 박성욱(2,3), 최신영(1), 문가영(1), 김정훈(2,3,4), 이기황(1) |
|
목적 : To investigate the effects of dyslipidemia and statin therapy on progression of diabetic retinopathy (DR) and diabetic macular edema (DME) in patients with type 2 diabetes.
방법 : The medical records of 110 patients with type 2 diabetes (70 statin users and 40 non-users) were retrospectively reviewed. The two outcome measures were progression of DR by two or more steps on the Early Treatment Diabetic Retinopathy Study scale and DME based on optical coherence tomography. Serum lipid profiles were analyzed from 6 months prior to diagnosis of DME.
결과 : DR progressed in 23% of statin users and 18% of non-users (p = 0.506), but DME was present in 23% of statin users and 48% of non-users (p = 0.008). Statins reduced LDL cholesterol levels in patients with and without DME (p = 0.043 and p = 0.031, respectively). Among statin users, patients with DME had higher levels of triglycerides (p = 0.004) and lower levels of HDL cholesterol (p = 0.033) than those without DME. Hypertriglyceridemia at 6 months prior to development of DME was significantly associated with central retinal thickness (OR: 1.52; 95% CI: 1.14–2.02, p = 0.005).
결론 : Lipid lowering therapy with statins protected against the development of DME and progression of DR in patients with type 2 diabetes. Hypertriglyceridemia could be used as a surrogate marker for DME.
|
| |